$ULBI

Insider Buying: Ultralife (NASDAQ:ULBI) Director Buys $458,326.62 in Stock

Ultralife (NASDAQ:ULBI) director Bradford Whitmore bought 67,302 shares on May 26 at an average $6.81, for $458,326.62, according to an SEC filing. Post-trade, he owned 2,050,637 shares (~$13.96M). The stock trades near $7.76. On May 8, Ultralife reported Q results of -$0.03 EPS and $47.45M revenue, below consensus.

Original reporting
Published May 29, 2026, 9:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Insider Buying: Ultralife (NASDAQ:ULBI) Director Buys $458,326.62 in Stock — source image
Decision brief

The 30-second read

$ULBIBullishLow
01

Why it matters

The insider transaction can improve sentiment and reduce perceived downside risk, but the recent earnings miss and small market cap suggest the effect may be muted unless accompanied by guidance/contract updates.

02

Market read

Traders may use the insider buy as a sentiment input, but the dominant fundamental datapoint in the article remains the May 8 earnings miss.

03

What to watch

The stock’s P/E is negative and the article highlights weak profitability (negative net margin), so insider buying may be insufficient to change valuation without new guidance or contract wins.

Relevance 6/10Novelty 6/10Timing: Pre-market/early session after the May 26 insider buy disclosure

Background

The piece centers on a Form 4-style disclosure of director buying, alongside a recap of the May 8 quarterly earnings results (EPS miss and revenue below estimates).

Company-level read

Ticker impact

$ULBIBullishMedium confidence
Context

Ultralife director Bradford Whitmore bought 67,302 shares at $6.81, increasing his stake by 3.39% per SEC-disclosed transaction.

Expected impact

Near-term reaction likely limited; watch for follow-through if selling pressure fades after the Form 4.

Evidence & confidence

The article provides a concrete ownership increase (Form 4) but no new operating catalyst beyond the already-reported May 8 earnings miss.

Market effects

Limited direct sector read-through; insider buying is company-specific rather than a battery/defense demand signal.

None indicated; US small-cap trading focus.

None indicated.

Counterpoint

Insider buys can be routine (e.g., planned purchases) and may not offset fundamental concerns from the prior quarter’s revenue/EPS miss.

Key entities

  • Ultralife Corporation

    NASDAQ-listed energy/communications products maker; subject of the director insider-buy disclosure.

  • Bradford Whitmore

    Ultralife director who purchased 67,302 shares at an average $6.81.

Related articles

$ENSHighAI 9/10

EnerSys to Acquire Ultralife for $16 Per Share in Cash

EnerSys (ENS) agreed to acquire Ultralife for $16 per share in cash. The deal, subject to regulatory approvals, includes support from shareholders holding 40.3% of Ultralife's shares. The tender offer is expected to start within 10 business days and may close by April 27, 2027, with possible extensions.

$ENSHighAI 9/10

EnerSys to acquire Ultralife for $320 million in cash

EnerSys (ENS) agreed to acquire Ultralife (ULBI) for $320 million in cash, including debt. Ultralife shareholders will receive $16.00 per share, a 166% premium over Monday's closing price. The deal, approved by both boards, is expected to close in Q1 2027. EnerSys will finance the acquisition with available cash. Both companies' CEOs cited strategic benefits and value creation.

$ULBIMedAI 8/10

Ultralife (ULBI) Q2 2026 Earnings Call Transcript

Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.

$ULBIMed

Ultralife Corporation Reports Second Quarter Results

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results: ● Sales of $47.9 million compared to $48.6 mil